Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Traws Pharma (TRAW) EBIT Margin (2016 - 2025)

Traws Pharma's EBIT Margin history spans 14 years, with the latest figure at 45.7% for Q2 2025.

  • Quarterly results put EBIT Margin at 45.7% for Q2 2025, up 21635430.0% from a year ago — trailing twelve months through Dec 2025 was 640.68% (up 6235666.0% YoY), and the annual figure for FY2025 was 640.68%, up 6235666.0%.
  • EBIT Margin for Q2 2025 was 45.7% at Traws Pharma, up from 9128.07% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 45.7% in Q2 2025 to a low of 216400.0% in Q2 2024.
  • The 5-year median for EBIT Margin is 8538.6% (2021), against an average of 19952.94%.
  • The sharpest move saw EBIT Margin plummeted -20831228bps in 2024, then soared 21635430bps in 2025.
  • Year by year, EBIT Margin stood at 6719.64% in 2021, then plummeted by -52bps to 10239.29% in 2022, then increased by 22bps to 7967.86% in 2023, then dropped by -18bps to 9425.0% in 2024, then surged by 100bps to 45.7% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 45.7%, 9128.07%, and 9425.0% for Q2 2025, Q1 2025, and Q4 2024 respectively.